New vaccine candidate provides breakthrough in the fight against malaria
3 min read
fairly difficult
A malaria vaccine candidate tested on children in West Africa has shown an efficacy of around 77 per cent, say scientists, hailing it as a breakthrough in the fight against the disease.
Malaria causes more than 400,000 deaths a year globally, according to the World Health Organization (WHO), mostly among children in Sub-Saharan Africa.

The R21/Matrix-M vaccine, developed by the Clinical Research Unit of Nanoro (CRUN), Burkina Faso and their partners at the University of Oxford in the UK, is the first malaria vaccine to reach the 75 per cent efficacy target set by the WHO.

Researchers recruited 450 children aged five to 17 months in the area of ​​Nanoro, central Burkina Faso, and divided them into three groups for the Phase IIb trial.

One group of 150 received the vaccine with a low dose of the Matrix-M adjuvant, which helps create a stronger immune response. Another group of 150 received the vaccine at a higher dose of adjuvant, while the last group of 150 received the rabies vaccine as a control vaccine.

Halidou Tinto, principal trial investigator at the CRUN, said:

Once we vaccinated them with three doses one month apart […], we followed them in each group to see how they were going to behave in terms of vaccine safety, tolerance, but also efficacy."

The subjects in the study reported no serious side effects from the vaccine,…
Read full article